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SUMMARY

The continual emergence of novel coronaviruses (CoV), such as severe acute respiratory syndrome-(SARS)CoV-2, highlights the critical need for broadly reactive therapeutics and vaccines against this family of viruses. From a recovered SARS-CoV donor sample, we identify and characterize a panel of six monoclonal
antibodies that cross-react with CoV spike (S) proteins from the highly pathogenic SARS-CoV and SARSCoV-2, and demonstrate a spectrum of reactivity against other CoVs. Epitope mapping reveals that these
antibodies recognize multiple epitopes on SARS-CoV-2 S, including the receptor-binding domain, the
N-terminal domain, and the S2 subunit. Functional characterization demonstrates that the antibodies
mediate phagocytosis—and in some cases trogocytosis—but not neutralization in vitro. When tested in vivo
in murine models, two of the antibodies demonstrate a reduction in hemorrhagic pathology in the lungs. The
identification of cross-reactive epitopes recognized by functional antibodies expands the repertoire of
targets for pan-coronavirus vaccine design strategies.

INTRODUCTION
The emergence of a novel coronavirus severe acute respiratory
syndrome-coronavirus-2 (SARS-CoV-2), the causative agent of
coronavirus disease 2019 (COVID-19), has resulted in a worldwide pandemic, threatening the lives of billions and imposing
an immense burden on healthcare systems and the global economy. SARS-CoV-2, the seventh coronavirus known to infect humans, is a member of the Betacoronavirus genus, which includes

the highly pathogenic SARS-CoV and Middle Eastern respiratory
syndrome (MERS)-CoV, as well as endemic variants HCoVOC43 and HCoV-HKU1.1 Recent coronavirus outbreaks and
the threat of future emerging zoonotic strains highlight the
need for broadly applicable coronavirus therapeutic interventions and vaccine design approaches.2
Coronaviruses use the homotrimeric spike (S) protein to
engage with cell-surface receptors and enter host cells. S consists of two functional subunits: S1 and S2. S1 facilitates the
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attachment to target cells and is composed of the N-terminal
domain (NTD) and the receptor-binding domain (RBD), whereas
S2, which encodes the fusion peptide and heptad repeats, promotes viral fusion.3,4 To facilitate cell entry, human coronaviruses use different host factors; however, SARS-CoV and
SARS-CoV-2 both use the cell-surface receptor angiotensinconverting enzyme 2 (ACE2).5 In addition, SARS-CoV-2 S shares
76% amino acid identity with SARS-CoV S.1 Furthermore, S
serves as a dominant antibody target and is a focus of countermeasure development for the treatment and prevention of
COVID-19 infection.6,7 S proteins from the Betacoronavirus
genus share multiple regions of structural homology and thus
could serve as targets for a cross-reactive antibody response.8
Identifying cross-reactive antibody epitopes can inform rational
design strategies for vaccines and therapies that target multiple
highly pathogenic coronaviruses.
Numerous potent neutralizing antibodies against SARSCoV-2 have been discovered, including multiple candidates
currently in clinical trials or approved for emergency use for
the prophylactic and acute treatment of COVID-19.9–16 Investigation of SARS-CoV-2/SARS-CoV cross-reactive antibodies
has focused primarily on the RBD epitope, which has resulted
in the identification of a number of SARS-CoV-2/SARSCoV cross-reactive antibody candidates.12,17,18 However, the
diversity of epitopes and functions beyond virus neutralization
have not been extensively explored for cross-reactive antibodies.19–21 Evidence of Fc effector function contributing to
protection in vivo against SARS-CoV22 and SARS-CoV-223 suggests that the role of antibodies beyond neutralization may be a
crucial component of protection and an important consideration
in vaccine design strategies for coronaviruses.20,24–26
In this study, we investigated antibody cross-reactivity across
the Betacoronavirus genus at monoclonal resolution. To do this,
we applied LIBRA-seq (linking B cell receptor to antigen specificity through sequencing)27 to a recovered SARS-CoV donor
sample from >10 years after infection. We identified and characterized SARS-CoV-2/SARS-CoV cross-reactive human antibodies that target multiple, distinct structural domains of S,
mediate phagocytosis and trogocytosis, and mitigate pathological burden in vivo. A better understanding of the genetic
features, epitope specificities, and functional characteristics of
cross-reactive coronavirus antibodies may translate into strategies for current vaccine design efforts and additional measures
to counteract potential future pandemic strains.
RESULTS
LIBRA-seq characterization of a SARS-CoV recovered
donor
To identify cross-reactive antibodies to multiple coronavirus
antigens, LIBRA-seq was applied to a peripheral blood mononuclear cell (PBMC) sample from a donor infected with SARSCoV >10 years before sample collection. The antigen screening
library consisted of eight oligo-tagged recombinant soluble antigens: six coronavirus trimer antigens (SARS-CoV-2 S, SARSCoV S, MERS-CoV S, MERS-CoV S1 [with foldon domain],
HCoV-OC43 S, and HCoV-HKU1 S) and two HIV trimer antigens
from strains ZM197 and CZA97 as negative controls (Figure 1A).
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After the antigen screening library was mixed with donor
PBMCs, antigen-positive B cells were enriched by fluorescence-activated cell sorting (FACS) and processed for singlecell sequencing (Figure S1A). After bioinformatic processing,
we recovered 2,625 cells with paired heavy-/light-chain sequences and antigen reactivity information (Figure S1B), and
from these cells, there were 2,368 unique VDJ (variability, diversity, and joining) sequences. Overall, LIBRA-seq enabled rapid
screening of PBMCs from a patient sample, with recovery of
paired heavy-/light-chain sequences and antigen reactivity for
thousands of B cells at the single-cell level.
Identification of SARS-CoV-2 and SARS-CoV crossreactive antibodies
With a goal of identifying antibodies that were cross-reactive to
multiple coronavirus S proteins, we prioritized lead candidates
based on their sequence features and LIBRA-seq scores (Figure S1C). We selected 15 antibody candidates that exhibited
diverse sequence features and used a number of different variable genes for expression and characterization (Figures 1B and
S1D). These antibodies displayed a broad range of percent identity to germline (83%–98%) and a variety of CDRH3 and CDRL3
lengths (6–24 and 5–13 amino acids, respectively) (Figure S1D).
By ELISA, SARS-CoV-2 S and SARS-CoV S binding was
confirmed for 6/15 of the tested antibodies (46472-1, 46472-2,
46472-3, 46472-4, 46472-6, and 46472-12), indicating that
LIBRA-seq could successfully identify SARS-CoV-2 reactive
B cells, but also suggesting potential differences in antigen-binding detection for primary B cells with a sequencing readout
versus recombinant immunoglobulin G (IgG) by ELISA (Figures
1C, 1D, and S1E). Furthermore, antibodies 46472-6 and
46472-12 bound to S proteins from endemic HCoV-OC43 and
HCoV-HKU1, albeit generally at lower levels (Figures 1C, 1D,
and S1E). Although the six monoclonal antibodies (mAbs)
showed reactivity by ELISA to the MERS-CoV antigen probe
used in the LIBRA-seq screening library, antibody binding to
other independent preparations of this protein was inconsistent,
so MERS-CoV S reactivity could not be confirmed definitively
(Figures S1F and S1G). Overall, the application of the LIBRAseq technology enabled the identification of a panel of crossreactive antibodies that recognize the S antigen from multiple
coronaviruses.
Cross-reactive CoV antibodies target diverse epitopes
on S
To elucidate the epitopes targeted by the cross-reactive antibodies, we performed binding assays to various structural
domains of S as well as binding-competition experiments. We
assessed antibody binding to the S1 and S2 subdomains of
SARS-CoV-2. Antibodies 46472-1, 46472-2, 46472-3, and
46472-4 bound to the S2 domain, whereas 46472-6 and
46472-12 recognized the S1 domain but targeted different epitopes, the NTD and RBD, respectively (Figures 2A–2C, S2A,
and S2B). Although 46472-12 bound to the RBD, it did not
compete with ACE2 for binding to SARS-CoV-2 S and showed
partial competition with RBD-directed antibody CR3022 (Figures S2C and S2D). To determine whether the antibodies
targeted overlapping or distinct epitopes, we performed
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Figure 1. Identification of coronavirus cross-reactive antibodies from SARS-CoV recovered PBMC sample using LIBRA-seq
(A) Schematic of DNA-barcoded antigens used to probe a SARS-CoV donor PBMC sample.
(B) LIBRA-seq scores for SARS-CoV (x axis) and SARS-CoV-2 (y axis) for all IgG+ B cells recovered from sequencing are shown as circles; 15 lead antibody
candidates are highlighted in purple.
(C) Antibodies were tested for binding to CoV antigens by ELISA. HIV-specific antibody VRC01 was used as a negative control. Anti-SARS-CoV mouse antibody
240CD was also used. ELISAs were performed in technical duplicates with at least 2 biological duplicates. Data are represented as means ± SEMs.
(D) ELISA binding data are displayed as a heatmap of the AUC values calculated from data in (C), with an area under the curve (AUC) of 0 as white, and maximum
AUC as purple.
See also Figure S1.

competition ELISA experiments and found that the S2-directed
antibodies 46472-1, 46472-2, and 46472-4 competed for binding to S (Figure 2D). This pattern was observed for both SARSCoV-2 and SARS-CoV S. Of note, this competition group did

not include S2-directed antibody 46472-3, revealing the identification of multiple cross-reactive epitope targets on S2 (Figure 2D). Furthermore, antibody binding was not affected by
two glycan knockout mutants (N165A or N709A) or mannose
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competition (Figures S2E and S2F). Lastly, we measured antibody autoreactivity and found that with the exception of
46472-6 binding to Jo-1, none of the antibodies showed autoreactivity against the tested antigens (Figure 2E). These data
suggest that the identified cross-reactive antibodies are coronavirus specific and target multiple, diverse epitopes on the S
protein (Figure 2F).
Functional characterization of cross-reactive CoV
antibodies
Next, we characterized our cross-reactive antibody panel for
functional activity. Although none of the antibodies neutralized
SARS-CoV or SARS-CoV-2 (Figures S3A and S3B), all of the antibodies showed antibody-dependent cellular phagocytosis
(ADCP) in vitro for SARS-CoV-2 S (Figures 3A and S3C). In
particular, the RBD-reactive antibody 46472-12 showed greater

Figure 3. Functional activity of cross-reactive coronavirus antibodies
(A) Cross-reactive coronavirus antibodies were
tested for antibody-dependent cellular phagocytosis
activity (ADCP) against SARS-CoV-2 S, compared to
positive control CR3022 and negative control
palivizumab, an anti-RSV antibody. AUC of the
phagocytosis score is shown, calculated from data in
Figure S3C. Data are represented as means ± SDs.
(B) 46472-4 and 46472-12 were tested for ADCP
activity against SARS-CoV S, compared to CR3022
and anti-RSV palivizumab. AUC of the phagocytosis score is shown, calculated from data in Figure S3D. Data are represented as means ± SDs.
(C) Cross-reactive coronavirus antibodies were
tested for antibody-dependent cellular trogocytosis
(ADCT) activity against SARS-CoV-2 S displayed on
transfected cells, compared to positive control
CR3022 and anti-RSV palivizumab. AUC of the trogocytosis score is shown, calculated from data in
Figure S3E. Data are represented as means ± SDs.
(D) Cross-reactive coronavirus antibodies were
tested for antibody-dependent complement deposition (ADCD) activity against SARS-CoV-2 S,
compared to positive control CR3022 and anti-RSV
palivizumab. AUC of the C3b deposition score is
shown, calculated from data in Figure S3F. Data are
represented as means ± SDs.
See also Figure S3.

ADCP activity compared to the other cross-reactive antibodies
and the SARS-CoV/SARS-CoV-2 cross-reactive RBD antibody
control, CR302228 (Figures 3A and S3C). Furthermore, we tested
and confirmed ADCP activity against SARS-CoV for two antibodies that mediated the highest phagocytotic activity against
SARS-CoV-2, 46472-4, and 46472-12, illustrating that these antibodies have cross-coronavirus phagocytic ability (Figures 3B
and S3D). We next tested the antibodies in a trogocytosis
assay29 and found that four antibodies in our panel (46472-1,
46472-2, 46472-3, and 46472-4) mediated trogocytosis (Figures
3C and S3E). This warrants further investigation as this is the first
description of trogocytosis performed by SARS-CoV-2-specific
antibodies. Lastly, there was no antibody-dependent complement deposition (ADCD) (Figures 3D and S3F). These results revealed different profiles of Fc effector functionality within the
panel of cross-reactive antibodies.

Figure 2. Epitope mapping of cross-reactive antibodies
(A) For cross-reactive coronavirus antibodies, ELISA data against the antigens are displayed as a heatmap of the AUC values calculated from the data in Figure S2A.
(B) For SARS-CoV-2 S1-reactive antibodies, ELISA data against the RBD and NTD are displayed as a heatmap of the AUC values calculated from the data in
Figure S2B. For (A) and (B), an AUC of 0 is displayed as white and maximum AUC as purple. ELISA data are representative of at least 2 independent experiments.
Anti-HIV antibody VRC01 and anti-vascular endothelial growth factor (VEGF) antibody are shown as a negative control, and anti-SARS-CoV antibody 240CD is
shown as a positive control.
(C) Surface plasmon resonance binding of 46472-12 Fab to SARS-CoV-2 RBD. Calculated binding constants are shown to the right of the graph.
(D) Cross-reactive antibodies were used in a competition ELISA to determine whether the binding of one antibody affected the binding of another. Competitor
antibodies were added at 10 mg/mL, and then detected antibodies were added at 0.1 mg/mL. The percent reduction in binding compared to binding without a
competitor is shown. An anti-HIV antibody was used as a negative control. ELISAs were performed in technical duplicates with at least 2 biological duplicates.
(E) Antibodies were tested for autoreactivity against a variety of antigens in the Luminex AtheNA assay. AU stands for Athena units. Anti-HIV antibody 4E10 was
used as a positive control and Ab82 was used as a negative control.
(F) Cross-reactive coronavirus antibodies target a variety of epitopes on the SARS-CoV-2 S protein, including the RBD, NTD, and S2 domains, highlighted on the
structure (PDB: 6VSB).
See also Figure S2.
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Figure 4. In vivo effects of cross-reactive antibodies
(A) Timeline of the prophylactic antibody experiment in SARS-CoV-2 mouse adapted (MA) in vivo infection model.
(B and C) For each antibody treatment group for the experiment using (B) 1 3 103 PFU or (C) 1 3 104 PFU of SARS-CoV-2 MA, shown are daily body weight
progression, and terminal qRT-PCR quantification of lung viral titer and lung hemorrhage scores of gross pathology. For viral titer values and the lung hemorrhage
scores, an ordinary one-way ANOVA test with multiple comparisons was performed; **p < 0.01 and ***p < 0.001.
(D) For the experiment with 1 3 104 PFU of SARS-CoV-2 MA, percent survival for each antibody group is shown.
See also Figure S4.
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Since non-neutralizing SARS-CoV-2 antibodies with Fc
effector function activity have not been extensively characterized
in vivo, these results prompted us to test antibodies 46472-4 and
46472-12 for prophylaxis in a murine infection model using a
mouse-adapted virus strain (SARS-CoV-2 MA)30,31 at a non-lethal dose of 1 3 103 plaque-forming units (PFU) (Figure 4A).
Although there were no differences in survival and viral load between experimental and control groups, the lung hemorrhage
scores (see Method details) for 46472-4 and 46472-12 were
similar to antigen-specific control CR3022, and all three groups
were significantly lower than the scores for isotype control
DENV-2D22 (p < 0.01, ordinary one-way ANOVA with multiple
comparisons) (Figures 4B and S4A). To evaluate the in vivo effect
of these antibodies in a more stringent challenge model in
12-month-old female BALB/c mice, we increased the viral dose
from 1 3 103 to 1 3 104 PFU. In this experiment, mice that
received antibody 46472-12 exhibited the best survival rate
(4/5 at day 4), compared to the other treatment groups that
included CR3022 as an antigen-specific control and DENV2D22 as a negative control, although statistical significance
was not achieved (Figures 4C, 4D, and S4B). There were no significant differences in viral load between groups; however, the
surviving animals from the 46472-4 and 46472-12 groups
showed significantly lower hemorrhagic pathology scores in harvested mouse lungs compared to the negative control treatment
group (p < 0.001, ordinary one-way ANOVA with multiple comparisons) (Figure 4C). Animals treated with the antigen-specific
control, CR3022, had significantly higher hemorrhage scores
than animals treated with 46472-4 and 46472-12 (p < 0.001, ordinary one-way ANOVA with multiple comparisons), although
the statistical analysis may be limited by the small numbers of
surviving animals for some of the groups (Figure 4C). While definitive evidence for protection is limited, the data from the in vivo
experiments suggest that these cross-reactive antibodies could
contribute to counteracting coronavirus infection in prophylaxis.
DISCUSSION
Here, we described a set of cross-reactive Betacoronavirus
antibodies isolated from a recovered SARS-CoV donor. The
antibodies targeted diverse epitopes on S, including the S2 subdomain as well as the RBD and NTD on S1, and demonstrated Fc
effector function in vitro. In addition, two of these antibodies
were tested in vivo and displayed a reduction in lung hemorrhage
score, while the effects on viral load were not definitive.
Given the similar effect of 46472-4 and 46472-12 on severe
disease in the mouse model, their phagocytotic ability along
with the inability to mediate neutralization suggests that the
former may be a mechanism through which they function, and
additional studies are under way to further assess this hypothesis. Phagocytosis has been shown to be associated with protection in a SARS-CoV-2 DNA vaccination in non-human primates32
as well as survival in natural infection,33 and as such could be an
important mechanism for protection by antibodies.20 The role of
trogocytosis in COVID-19 is unknown, as are the targets that
may be important for this function. 46472-4 was able to mediate
this membrane nibbling in contrast to 46472-12, suggesting that
this function in addition to complement activity was not respon-

sible for the in vivo effect on severe disease mediated by these
antibodies. Although the precise in vivo effects of these antibodies have not been elucidated, the identification of multiple,
cross-reactive antibodies highlights a potential role for Fc
effector function activity, specifically phagocytosis, in coronavirus infection. Evidence of protection associated with Fc effector
function in SARS-CoV,22 SARS-CoV-2,23,24,34 and other infectious diseases, including influenza, Ebola, and HIV, motivates
further investigation into its contribution to the treatment of
COVID-19.35–38 Furthermore, the importance of Fc effector functionality of potently neutralizing candidate clinical SARS-CoV-2
antibodies in a therapeutic setting rather than prophylaxis highlights the potential benefit for investigation into non-neutralizing
antibodies with phagocytic activity and their administration after
infection onset.39 Elucidation of the functional roles of crossreactive but non-neutralizing antibodies could have implications
for understanding the factors involved in the protection or
enhancement of disease.
Given the ongoing SARS-CoV-2 pandemic and the potential
for future zoonotic coronavirus pathogens to emerge, coronavirus vaccine and therapeutic development is of paramount
importance.40–43 Antibodies that can cross-react with multiple
coronavirus strains are primary targets as potential broadly reactive therapies. Such antibodies can further reveal cross-reactive
epitopes that could serve as templates for the development of
broadly protective vaccines. Understanding the spectrum of
cross-reactive epitopes targeted by human antibodies, as well
as the functional role that such antibodies have within coronavirus infection, are therefore a vital element of medical countermeasure development.
Limitations of the study
The present study focuses on the characterization of cross-reactive coronavirus antibodies, mostly in the context of SARSCoV-2. Further characterization of this panel of antibodies
against circulating endemic coronavirus strains would enhance
the clinical relevance to less severe coronavirus-associated respiratory infections.
The present study used a dosing regimen in a prophylactic
setting, and given the emerging evidence of survival benefit
with effector function in antibodies provided after infection
onset,39 antibody administration in a therapeutic setting may
provide further insight into in vivo properties. Furthermore, additional effector function characterization such as ADCC and
ADNP would strengthen the profile of this panel of non-neutralizing antibodies, considering their role in both human33 and
mouse SARS-CoV-2 infection studies.
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RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to the Lead Contact, Ivelin Georgiev (Ivelin.
Georgiev@Vanderbilt.edu).
Materials availability
All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement. Please direct resource and reagent requests to the Lead Contact specified above, Ivelin Georgiev.
Data and code availability
Sequences for antibodies identified and characterized in this study have been deposited to GenBank under GenBank accession
numbers MZ126644-MZ126658 (heavy chain) and MZ126659-MZ126673 (light chain). Raw sequencing data used in this study
are available on the Sequence Read Archive under BioProject accession number PRJNA727275. Custom scripts used to analyze
data in this manuscript are available upon request to the corresponding author.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human subjects
The donor had prior SARS-CoV infection during the 2004 outbreak in Hong Kong, and the PBMC sample was collected over 10 years
post infection (20 million PBMCs). Additional information about the donor is not available.
Cell lines
A variety of cell lines were utilized for various assays in this study.
Expi293F mammalian cells (ThermoFisher) were maintained in FreeStyle F17 expression medium supplemented at final concentrations of 0.1% Pluronic Acid F-68 and 20% 4mM L-Glutamine. These cells were cultured at 37 C with 8% CO2 saturation and
shaking.
FreeStyle293F cells were grown while shaking at 37 C in 8% CO2 and 80% humidity. Freestyle293F cells are derived from female
human embryonic kidney epithelial cells.
THP-1 cells obtained from the AIDS Reagent Program (Division of AIDS, NIAID, NIH contributed by Dr. Li Wu and Vineet N. KewalRamani) were used for both the ADCP and ADCT assays. Cells were cultured at 37 C, 5% CO2 in RPMI containing 10% heatinactivated fetal bovine serum (GIBCO, Gaithersburg, MD), 1% Penicillin Streptomycin (GIBCO, Gaithersburg, MD) and
2-mercaptoethanol to a final concentration of 0.05 mM. These cells were not allowed to exceed 4 3 105 cells/ml to prevent differentiation and are from a male donor.
HEK293T cells were obtained from Dr George Shaw and were used for the ADCT assay. These adherent cell lines were cultured at
37 C, 5% CO2, in DMEM containing 10% heat-inactivated fetal bovine serum (GIBCO BRL Life Technologies) and supplemented
with 50 mg/ml gentamicin (Sigma). Cells were disrupted at confluence with 0.25% trypsin in 1 mM EDTA (Sigma) every 48–72 hours.
HEK293F suspension cells were cultured in 293Freestyle media (GIBCO BRL Life Technologies) and grown in a shaking incubator at
37 C, 5% CO2, 70% humidity at 125rpm. Cells were diluted twice a week to between 0.2 and 0.5 million cells/ml. Both HEK293
derived cell lines are from female donors.
Murine model
12-month old female BALB/c mice (BALB/cAnHsd; Envigo, stock number 047) were used in a murine infection model for SARS-CoV2 with a mouse adapted strain.
Eleven to twelve-month old female BALB/c mice (BALB/c AnNHsd, Envigo, stock# 047) were used for mouse-adapted SARS-CoV2 (SARS-CoV-2 MA10) in vivo protection experiments as described previously.31 All mouse studies were performed at the University
of North Carolina (Animal Welfare Assurance #A3410-01) using protocols (19-168) approved by the UNC Institutional Animal Care and
Use Committee (IACUC) and were performed in a BSL3 facility at UNC.
METHOD DETAILS
Antigen purification
A variety of recombinant soluble protein antigens were used in the LIBRA-seq experiment and other experimental assays.
Plasmids encoding residues 1–1208 of the SARS-CoV-2 spike with a mutated S1/S2 cleavage site, proline substitutions at positions 986 and 987, and a C-terminal T4-fibritin trimerization motif, an 8x HisTag, and a TwinStrepTag (SARS-CoV-2 S-2P); residues
1-1190 of the SARS-CoV spike with proline substitutions at positions 968 and 969, and a C-terminal T4-fibritin trimerization motif, an
8x HisTag, and a TwinStrepTag (SARS-CoV S-2P); residues 1-1291 of the MERS-CoV spike with a mutated S1/S2 cleavage site,
proline substitutions at positions 1060 and 1061, and a C-terminal T4-fibritin trimerization motif, an AviTag, an 8x HisTag, and
a TwinStrepTag (MERS-CoV S-2P Avi); residues 1-751 of the MERS-CoV spike with a C-terminal T4-fibritin trimerization motif,
8x HisTag, and a TwinStrepTag (MERS-CoV S1); residues 1-1277 of the HCoV-HKU1 spike with a mutated S1/S2 cleavage site, proline substitutions at positions 1067 and 1068, and a C-terminal T4-fibritin trimerization motif, an 8x HisTag, and a TwinStrepTag
(HCoV-HKU1 S-2P); residues 1-1278 of the HCoV-OC43 spike with proline substitutions at positions 1070 and 1071, and a C-terminal
T4-fibritin trimerization motif, an 8x HisTag, and a TwinStrepTag (HCoV-OC43 S-2P); or residues 319–591 of SARS-CoV-2 S with a
C-terminal monomeric human IgG Fc-tag and an 8x HisTag (SARS-CoV-2 RBD-SD1) were transiently transfected into FreeStyle293F
cells (Thermo Fisher) using polyethylenimine. The coronavirus trimer spike antigens were in a prefusion-stabilized (S-2P) conformation that better represents neutralization-sensitive epitopes in comparison to their wild-type forms51. Two hours post-transfection,
cells were treated with kifunensine to ensure uniform glycosylation. Transfected supernatants were harvested after 6 days of expression. SARS-CoV-2 RBD-SD1 was purified using Protein A resin (Pierce), SARS-CoV-2 S-2P, SARS-CoV S-2P, MERS-CoV S-2P Avi,
MERS-CoV S1, HCoV-HKU1 S-2P and HCoV-OC43 S-2P were purified using StrepTactin resin (IBA). Affinity-purified SARS-CoV-2
RBD-SD1 was further purified over a Superdex75 column (GE Life Sciences). MERS-CoV S1 was purified over a Superdex200
Increase column (GE Life Sciences). SARS-CoV-2 S-2P, SARS-CoV S-2P, MERS-CoV S-2P Avi, HCoV-HKU1 S-2P and HCoVOC43 S-2P were purified over a Superose6 Increase column (GE Life Sciences).
For the HIV-1 gp140 SOSIP variant from strain ZM197 (clade C) and CZA97 (clade C), recombinant, soluble antigens contained an
AviTag and were expressed in Expi293F cells using polyethylenimine transfection reagent and cultured. FreeStyle F17 expression
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medium supplemented with pluronic acid and glutamine was used. The cells were cultured at 37 C with 8% CO2 saturation and
shaking. After 5-7 days, cultures were centrifuged and supernatant was filtered and run over an affinity column of agarose bound
Galanthus nivalis lectin. The column was washed with PBS and antigens were eluted with 30 mL of 1M methyl-a-D-mannopyranoside. Protein elutions were buffer exchanged into PBS, concentrated, and run on a Superdex 200 Increase 10/300 GL Sizing column
on the AKTA FPLC system. Fractions corresponding to correctly folded protein were collected, analyzed by SDS-PAGE and antigenicity was characterized by ELISA using known monoclonal antibodies specific to each antigen. Avi-tagged antigens were biotinylated using BirA biotin ligase (Avidity LLC). Non-Avi-tagged antigens were biotinylated using the EZ-Link Sulfo-NHS-Biotin kits
using a 50:1 biotin to protein molar ratio.
For binding studies, SARS-CoV-2 HexaPro S, SARS-CoV S, SARS-CoV-2 RBD, SARS-CoV RBD, and MERS-CoV RBD constructs
were expressed in the transient expression system previously mentioned. S proteins were purified using StrepTrap HP columns and
RBD constructs were purified over protein A resin, respectively. Each resulting protein was further purified to homogeneity by sizeexclusion chromatography on a Superose 6 10/300 GL column.
SARS-CoV-2 S1, SARS-CoV-2 S1 D614G, SARS-CoV-2 S2, and SARS-CoV-2 NTD truncated proteins were purchased from the
commercial vendor, Sino Biological.
DNA-barcoding of antigens
We used oligos that possess 15 bp antigen barcode, a sequence capable of annealing to the template switch oligo that is part of the
10X bead-delivered oligos, and contain truncated TruSeq small RNA read 1 sequences in the following structure: 50 -CCT
TGGCACCCGAGAATTCCANNNNNNNNNNNNNCCCATATAAGA*A*A-3 0 , where Ns represent the antigen barcode. We used the
following antigen barcodes: GCTCCTTTACACGTA (SARS-CoV-2 S), TGACCTTCCTCTCCT (SARS-CoV S), ACAATTTGTCTGCGA
(MERS-CoV S), TCCTTTCCTGATAGG (MERS-CoV S1), CAGGTCCCTTATTTC (HCoV-HKU1 S), TAACTCAGGGCCTAT (HCoVOC43 S), CAGCCCACTGCAATA (CZA97), and ATCGTCGAGAGCTAG (ZM197). Oligos were ordered from IDT with a 50 amino modification and HPLC purified.
For each antigen, a unique DNA barcode was directly conjugated to the antigen itself. In particular, 50 amino-oligonucleotides were
conjugated directly to each antigen using the Solulink Protein-Oligonucleotide Conjugation Kit (TriLink cat no. S-9011) according to
manufacturer’s instructions. Briefly, the oligo and protein were desalted, and then the amino-oligo was modified with the 4FB crosslinker, and the biotinylated antigen protein was modified with S-HyNic. Then, the 4FB-oligo and the HyNic-antigen were mixed
together. This causes a stable bond to form between the protein and the oligonucleotide. The concentration of the antigen-oligo conjugates was determined by a BCA assay, and the HyNic molar substitution ratio of the antigen-oligo conjugates was analyzed using
the NanoDrop according to the Solulink protocol guidelines. AKTA FPLC was used to remove excess oligonucleotide from the protein-oligo conjugates, which were also verified using SDS-PAGE with a silver stain. Antigen-oligo conjugates were also used in flow
cytometry titration experiments.
Antigen specific B cell sorting
Cells were stained and mixed with DNA-barcoded antigens and other antibodies, and then sorted using fluorescence activated cell
sorting (FACS). First, cells were counted and viability was assessed using Trypan Blue. Then, cells were washed three times with
DPBS supplemented with 0.1% bovine serum albumin (BSA). Cells were resuspended in DPBS-BSA and stained with cell markers
including viability dye (Ghost Red 780), CD14-APC-Cy7, CD3-FITC, CD19-BV711, and IgG-PE-Cy5. Additionally, antigen-oligo conjugates were added to the stain. After staining in the dark for 30 minutes at room temperature, cells were washed three times with
DPBS-BSA at 300 g for five minutes. Cells were then incubated for 15 minutes at room temperature with Streptavidin-PE to label cells
with bound antigen. Cells were washed three times with DPBS-BSA, resuspended in DPBS, and sorted by FACS. Antigen positive
cells were bulk sorted and delivered to the Vanderbilt Technologies for Advanced Genomics (VANTAGE) sequencing core at an
appropriate target concentration for 10X Genomics library preparation and subsequent sequencing. FACS data were analyzed using
FlowJo.
Sample and library preparation, and sequencing
Single-cell suspensions were loaded onto the Chromium Controller microfluidics device (10X Genomics) and processed using the B
cell Single Cell V(D)J solution according to manufacturer’s suggestions for a target capture of 10,000 B cells per 1/8 10X cassette,
with minor modifications in order to intercept, amplify and purify the antigen barcode libraries as previously described.27
Sequence processing and bioinformatic analysis
We utilized and modified our previously described pipeline to use paired-end FASTQ files of oligo libraries as input, process and
annotate reads for cell barcode, UMI, and antigen barcode, and generate a cell barcode - antigen barcode UMI count matrix.27
BCR contigs were processed using Cell Ranger (10X Genomics) using GRCh38 as reference. Antigen barcode libraries were also
processed using Cell Ranger (10X Genomics). The overlapping cell barcodes between the two libraries were used as the basis of
the subsequent analysis. We removed cell barcodes that had only non-functional heavy chain sequences as well as cells with multiple
functional heavy chain sequences and/or multiple functional light chain sequences, reasoning that these may be multiplets. Additionally, we aligned the BCR contigs (filtered_contigs.fasta file output by Cell Ranger, 10X Genomics) to IMGT reference genes using
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HighV-Quest.47 The output of HighV-Quest was parsed using ChangeO48 and merged with an antigen barcode UMI count matrix.
Finally, we determined the LIBRA-seq score for each antigen in the library for every cell as previously described.27
Antibody expression and purification
For each antibody, variable genes were inserted into custom plasmids encoding the constant region for the IgG1 heavy chain as well
as respective lambda and kappa light chains (pTwist CMV BetaGlobin WPRE Neo vector, Twist Bioscience). Antibodies were
expressed in Expi293F mammalian cells (ThermoFisher) by co-transfecting heavy chain and light chain expressing plasmids using
polyethylenimine transfection reagent and cultured for 5-7 days. Cells were maintained in FreeStyle F17 expression medium supplemented at final concentrations of 0.1% Pluronic Acid F-68 and 20% 4mM L-Glutamine. These cells were cultured at 37 C with 8%
CO2 saturation and shaking. After transfection and 5-7 days of culture, cell cultures were centrifuged and supernatant was 0.45 mm
filtered with Nalgene Rapid Flow Disposable Filter Units with PES membrane. Filtered supernatant was run over a column containing
Protein A agarose resin equilibrated with PBS. The column was washed with PBS, and then antibodies were eluted with 100 mM
Glycine HCl at 2.7 pH directly into a 1:10 volume of 1M Tris-HCl pH 8.0. Eluted antibodies were buffer exchanged into PBS 3 times
using Amicon Ultra centrifugal filter units and concentrated. Antibodies were analyzed by SDS-PAGE. Additionally, antibodies 464721, 46472-2, 46472-3, 46472-4, 46472-6 and 46472-12 were assessed by size exclusion chromatography on a Superdex 200 Increase
10/300 GL Sizing column with the AKTA FPLC system.
High-throughput antibody expression
For high-throughput production of recombinant antibodies, approaches were used that are designated as microscale. For antibody
expression, microscale transfection were performed (1cml per antibody) of CHO cell cultures using the GIBCO ExpiCHO Expression System and a protocol for deep 96-well blocks (Thermo Fisher Scientific). In brief, synthesized antibody-encoding DNA (2cmg
per transfection) was added to OptiPro serum free medium (OptiPro SFM), incubated with ExpiFectamine CHO Reagent and added
to 800cml of ExpiCHO cell cultures into 96-deep-well blocks using a ViaFlo 384 liquid handler (Integra Biosciences). The plates were
incubated on an orbital shaker at 1,000crpm with an orbital diameter of 3cmm at 37c C in 8% CO2. The next day after transfection,
ExpiFectamine CHO Enhancer and ExpiCHO Feed reagents (Thermo Fisher Scientific) were added to the cells, followed by 4cd incubation for a total of 5cd at 37c C in 8% CO2. Culture supernatants were collected after centrifuging the blocks at 450g for 5cmin
and were stored at 4 C until use. For high-throughput microscale antibody purification, fritted deep-well plates were used containing
25cml of settled protein G resin (GE Healthcare Life Sciences) per well. Clarified culture supernatants were incubated with protein G
resin for mAb capturing, washed with PBS using a 96-well plate manifold base (QIAGEN) connected to the vacuum and eluted into
96-well PCR plates using 86cml of 0.1cM glycine-HCL buffer pHc2.7. After neutralization with 14cml of 1cM Tris-HCl pHc8.0, purified
mAbs were buffer-exchanged into PBS using Zeba Spin Desalting Plates (Thermo Fisher Scientific) and stored at 4 C until use.
ELISA
To assess antibody binding, soluble protein was plated at 2 mg/ml overnight at 4 C. The next day, plates were washed three times
with PBS supplemented with 0.05% Tween-20 (PBS-T) and coated with 5% milk powder in PBS-T. Plates were incubated for one
hour at room temperature and then washed three times with PBS-T. Primary antibodies were diluted in 1% milk in PBS-T, starting
at 10 mg/ml with a serial 1:5 dilution and then added to the plate. The plates were incubated at room temperature for one hour and then
washed three times in PBS-T. The secondary antibody, goat anti-human IgG conjugated to peroxidase, was added at 1:10,000 dilution in 1% milk in PBS-T to the plates, which were incubated for one hour at room temperature. Goat anti-mouse secondary was used
for SARS-CoV specific control antibody 240CD (BEI Resources). Plates were washed three times with PBS-T and then developed by
adding TMB substrate to each well. The plates were incubated at room temperature for ten minutes, and then 1N sulfuric acid was
added to stop the reaction. Plates were read at 450 nm.
Data are represented as mean ± SEM for one ELISA experiment. ELISAs were repeated 2 or more times. The area under the curve
(AUC) was calculated using GraphPad Prism 8.0.0. For antibody 240CD, the following reagent was obtained through BEI Resources,
NIAID, NIH: Monoclonal Anti-SARS-CoV S Protein (Similar to 240C), NR-616.
Competition ELISA
Competition ELISAs were performed as described above, with some modifications. After coating with antigen and blocking, 25 mL of
non-biotinylated competitor antibody was added to each well at 10 mg/ml and incubated at 37 C for 10 minutes. Then, without
washing, 75 mL biotinylated antibody (final concentration of 0.1 mg/ml) was added and incubated at 37 C for 1 hour. After washing
three times with PBS-T, streptavidin-HRP was added at 1:10,000 dilution in 1% milk in PBS-T and incubated for 1 hour at room temperature. Plates were washed and substrate and sulfuric acid were added as described above. ELISAs were repeated at least 2
times. Data is shown as the % decrease in binding.
Autoreactivity
Monoclonal antibody reactivity to nine autoantigens (SSA/Ro, SS-B/La, Sm, ribonucleoprotein (RNP), Scl 70, Jo-1, dsDNA, centromere B, and histone) was measured using the AtheNA Multi-Lyte ANA-II Plus test kit (Zeus scientific, Inc, #A21101). Antibodies
were incubated with AtheNA beads for 30min at concentrations of 50, 25, 12.5 and 6.25 mg/mL. Beads were washed, incubated
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with secondary and read on the Luminex platform as specified in the kit protocol. Data were analyzed using AtheNA software. Positive (+) specimens received a score > 120, and negative (-) specimens received a score < 100. Samples between 100-120 were
considered indeterminate.
Mannose competition
Mannose competition ELISAs were performed as described above with minor modifications. After antigen coating and washing,
nonspecific binding was blocked by incubation with 5% FBS diluted in PBS for 1 hour at RT. Primary antibodies were diluted in
5% FBS-PBST ± 1M D-(+)-Mannose starting at 10 mg/ml with a serial 1:5 dilution and then added to the plate for 1 hour at RT. After
washing, antibody binding was detected with goat anti-human IgG conjugated to peroxidase and added at 1:10,000 dilution in 5%
FBS in PBS-T to the plates. After 1 hour incubation, plates were washed and substrate and sulfuric acid were added as described
above. Data shown is representative of three replicates.
Epitope mapping visualization
SARS-CoV-2 Spike (PDB-6VSB) was visualized using PyMOL software. Antibody epitopes were visualized on the SARS-CoV-2 spike
using a structure of the pre-fusion stabilized SARS-CoV-2 S-2P construct5 modeled in the molecular graphics software PyMOL (The
PyMOL Molecular Graphics System, Version 2.3.5 Schrödinger, LLC).
RTCA neutralization assay
To assess for neutralizing activity against SARS-CoV-2 strain 2019 n-CoV/USA_WA1/2020 (obtained from the Centers for Disease
Control and Prevention, a gift from N. Thornburg), we used the high-throughput RTCA assay and xCelligence RTCA HT Analyzer
(ACEA Biosciences) that has been described previously.11 After obtaining a background reading of a 384-well E-plate, 6,000
Vero-furin cells52 were seeded per well. Sensograms were visualized using RTCA HT software version 1.0.1 (ACEA Biosciences).
One day later, equal volumes of virus were added to antibody samples and incubated for 1ch at 37 C in 5%cCO2. mAbs were tested
in triplicate with a single (1:20) dilution. Virus–mAb mixtures were then added to Vero-furin cells in 384-well E-plates. Controls were
included that had Vero-furin cells with virus only (no mAb) and media only (no virus or mAb). E-plates were read every 8–12 h for 72 h
to monitor virus neutralization. At 32 h after virus-mAb mixtures were added to the E-plates, cell index values of antibody samples
were compared to those of virus only and media only to determine presence of neutralization.
Nano-luciferase neutralization assay
A full-length SARS-CoV-2 virus based on the Seattle Washington isolate and a full-length SARS-CoV virus based on the Urbani
isolate were designed to express luciferase and was recovered via reverse genetics and described previously.53,54 Viruses were
titered in Vero E6 USAMRID cells to obtain a relative light units (RLU) signal of at least 10X the cell only control background. Vero
E6 USAMRID cells were plated at 20,000 cells per well the day prior in clear bottom black walled 96-well plates (Corning 3904).
Neutralizing antibody serum samples were tested at a starting dilution of 1:40 and were serially diluted 4-fold up to eight dilution
spots. Antibody-virus complexes were incubated at 37C with 5% CO2 for 1 hour. Following incubation, growth media was removed
and virus-antibody dilution complexes were added to the cells in duplicate. Virus-only controls and cell-only controls were included in
each neutralization assay plate. Following infection, plates were incubated at 37C with 5% CO2 for 48 hours. After the 48 hour incubation, cells were lysed and luciferase activity was measured via Nano-Glo Luciferase Assay System (Promega) according to the
manufacturer specifications. SARS-CoV and SARS-CoV-2 neutralization titers were defined as the sample dilution at which a
50% reduction in RLU was observed relative to the average of the virus control wells.
SPR
His-tagged SARS-CoV-2 RBD-SD1 was immobilized to a NiNTA sensorchip to a level of 150 RUs using a Biacore X100. Serial dilutions of purified Fab 46472-12 were evaluated for binding, ranging in concentration from 1 to 0.25 mM. The resulting data were fit to a
1:1 binding model using Biacore Evaluation Software.
Fc effector function assays
Antibody-dependent cellular phagocytosis (ADCP)
Antibody-dependent cellular phagocytosis (ADCP) was performed using biotinylated SARS-CoV-2 or SARS-CoV S coated fluorescent neutravidin beads as previously described.55 Briefly, beads were incubated for two hours with antibodies at a starting concentration of 50 mg/ml and titrated five fold. CR3022 was used as a positive control while Palivizumab was used as a negative control.
Antibodies and beads were incubated with THP-1 cells overnight, fixed and interrogated on the FACSAria II. Phagocytosis score was
calculated as the percentage of THP-1 cells that engulfed fluorescent beads multiplied by the geometric mean fluorescence intensity
of the population in the FITC channel less the no antibody control.
Antibody-dependent cellular trogocytosis (ADCT)
ADCT was performed as described in and modified from a previously described study.29 HEK293T cells transfected with a SARSCoV-2 spike pcDNA vector were surface biotinylated with EZ-Link Sulfo-NHS-LC-Biotin as recommended by the manufacturer.
Fifty-thousand cells per well were incubated with antibody for 30 minutes starting at 25 mg/ml and titrated 5 fold. CR3022 was
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used as a positive control with Palivizumab as a negative. Following a RPMI media wash, these were then incubated with carboxyfluorescein succinimidyl ester (CFSE) stained THP-1 cells (5 X104 cells per well) for 1 hour and washed with 15mM EDTA/PBS followed by PBS. Cells were then stained for biotin using Streptavidin-PE and read on a FACSAria II. Trogocytosis score was determined as the proportion of CFSE positive THP-1 cells also positive for streptavidin-PE less the no antibody control.
Antibody-dependent complement deposition (ADCD)
Antibody-dependent complement deposition was performed as previously described.56 Briefly biotinylated SARS-Cov-2 S protein
was coated 1:1 onto fluorescent neutravidin beads for 2 hours at 37 degrees. These beads were incubated with 100ug/ml of antibody
for 1 hour and incubated with guinea pig complement diluted 1 in 50 with gelatin/veronal buffer for 15 minutes at 37 degrees. Beads
were washed at 2000 g twice in PBS and stained with anti-guinea pig C3b-FITC, fixed and interrogated on a FACSAria II. Complement deposition score was calculated as the percentage of C3b-FITC positive beads multiplied by the geometric mean fluorescent
intensity of FITC in this population less the no antibody or heat inactivated controls.
Antibody prophylaxis - murine model of infection
For evaluating the prophylactic efficacy of mAbs, 12-month old female BALB/c mice (BALB/cAnHsd; Envigo, stock number 047) were
treated with 200 mg mAb intraperitoneally (i.p.) 12 hours prior to virus inoculation. The next day, mice were administered intranasally
with 1x103 PFU or 1x104PFU of SARS-CoV-2 MA10, respectively. Mice were monitored daily for weight loss, morbidity, and mortality,
and after four days, mice were sacrificed and lung tissue was harvested for viral titer as measured by plaque assays. One lung lobe
was taken for pathological analysis and the other lobe was processed for qPCR and viral load determination as previously
described.31 For viral plaque assays, the caudal lobe of the right lung was homogenized in PBS, and the tissue homogenate was
then serial-diluted onto confluent monolayers of Vero E6 cells, followed by agarose overlay. Plaques were visualized with overlay
of Neutral Red dye on day 2 post infection. Gross pulmonary hemorrhage was observed at time of tissue harvest and scored on a
scale of 0 (no hemorrhage in any lobe, normal pink healthy lung) to 4 (complete hemorrhage in all lobes of the lung, completely
dark red lung).
For viral titer and hemorrhage score comparisons, an ordinary one-way ANOVA test with multiple comparisons was performed
using Prism software, GraphPad Prism version 8.0.
ACE2 binding inhibition assay
Wells of 384-well microtiter plates were coated with purified recombinant SARS-CoV-2 S-2P ectoprotein at 4 C overnight. Plates
were blocked with 2% non-fat dry milk and 2% normal goat serum in DPBS-T for 1 hr. Purified mAbs were diluted two-fold in blocking
buffer starting from 10 mg/mL in triplicate, added to the wells (20 mL/well), and incubated at ambient temperature. Recombinant human ACE2 with a C-terminal FLAG tag protein was added to wells at 2 mg/mL in a 5 mL/well volume (final 0.4 mg/mL concentration of
ACE2) without washing of antibody and then incubated for 40 min at ambient temperature. Plates were washed, and bound ACE2
was detected using HRP-conjugated anti-FLAG antibody and TMB substrate. ACE2 binding without antibody served as a control.
Experiment was done in biological replicate and technical triplicates, shown is representative of one replicate with positive control
mAb COV2-2196.11
Identification of residue-level mutants
Potential cross-reactive epitopes were identified based on sequence and structural homology. Reference sequences for each
Coronavirus S were obtained either from NCBI for SARS-CoV-2 (YP_009724390.1) and MERS-CoV (YP_009047204.1) or from Uniprot for SARS-CoV (P59594) of the spikes was then obtained using MUSCLE49 and the amino acid similarity to SARS-CoV-2 at each
residue position was calculated using the BLOSUM-62 scoring matrix.50 These scores were then used to color each residue position
on the SARS-CoV-2 S structure (PDB ID: 6VSB) in PyMOL (Schrodinger, version 2.3.5) in order to visualize surface patches and linear
epitopes with structural homology. These conserved regions were then visualized on the other human coronavirus spike structures
by retrieving them from the Protein Databank (SARS-CoV: 5X5B, MERS-CoV: 5W9I) and aligning them to the SARS-CoV-2 S
structure. Finally, the residue N165 was part of a conserved surface patches and was mutated to alanine and tested for binding
with antibodies. The N709A mutant tested was previously described in Acharya et al., BioRxiv (2020).
QUANTIFICATION AND STATISTICAL ANALYSIS
ELISA error bars (standard error of the mean) were calculated using GraphPad Prism version 8.0.0. ANOVA analysis (ordinary one
way ANOVA with multiple comparisons) was performed on viral load titers and hemorrhage scores from animal experiments using
GraphPad Prism version 8.0.0. Details of the statistical analyses can be found in the main text and figure captions.
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